BidaskClub upgraded shares of Amarin Corporation PLC (NASDAQ:AMRN) from a buy rating to a strong-buy rating in a report released on Thursday, July 6th.

AMRN has been the subject of a number of other reports. Jefferies Group LLC restated a buy rating and set a $5.00 price objective on shares of Amarin Corporation PLC in a research note on Monday, June 12th. Cantor Fitzgerald reiterated a buy rating and issued a $6.00 price target on shares of Amarin Corporation PLC in a research note on Thursday, March 16th. HC Wainwright reiterated a buy rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research note on Wednesday, June 28th. Finally, Zacks Investment Research upgraded shares of Amarin Corporation PLC from a hold rating to a buy rating and set a $3.50 price target for the company in a research note on Monday, April 3rd. Six equities research analysts have rated the stock with a buy rating, The stock has an average rating of Buy and an average target price of $7.35.

Amarin Corporation PLC (NASDAQ:AMRN) traded down 1.34% on Thursday, reaching $3.67. The company’s stock had a trading volume of 1,257,976 shares. Amarin Corporation PLC has a 12 month low of $2.56 and a 12 month high of $4.47. The firm’s 50 day moving average is $3.77 and its 200-day moving average is $3.29. The firm’s market cap is $993.83 million.

Amarin Corporation PLC (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The firm had revenue of $44.95 million for the quarter, compared to the consensus estimate of $40.35 million. The firm’s revenue for the quarter was up 37.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.07) earnings per share. On average, equities research analysts anticipate that Amarin Corporation PLC will post ($0.22) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Amarin Corporation PLC (AMRN) Upgraded by BidaskClub to Strong-Buy” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/04/amarin-corporation-plc-amrn-stock-rating-upgraded-by-bidaskclub-updated-updated-updated.html.

In related news, General Counsel Joseph T. Kennedy sold 307,911 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $4.00, for a total transaction of $1,231,644.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.72% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Amarin Corporation PLC by 126.9% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 101,690 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 56,881 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Amarin Corporation PLC by 662.8% in the fourth quarter. Renaissance Technologies LLC now owns 386,000 shares of the biopharmaceutical company’s stock valued at $1,189,000 after buying an additional 335,400 shares in the last quarter. Perkins Capital Management Inc. purchased a new position in shares of Amarin Corporation PLC during the first quarter valued at $110,000. Wells Fargo & Company MN increased its position in shares of Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Amarin Corporation PLC by 0.9% in the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock valued at $1,266,000 after buying an additional 3,413 shares in the last quarter. 37.55% of the stock is currently owned by institutional investors and hedge funds.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Stock Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related stocks with our FREE daily email newsletter.